A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) (Q32173730)

6 July 2017

title

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) (English)

1 reference

6 July 2017

main subject

phase II clinical trial

0 references

1 reference

5

Michael A Gorin

1 reference

6 July 2017

Noura Radwan

1

0 references

Curtiland Deville

Curtiland Deville

7

0 references

Phuoc T. Tran

Phuoc T Tran

20

0 references

Kenneth J. Pienta

15

Kenneth J Pienta

1 reference

6 July 2017

16

Martin G Pomper

1 reference

6 July 2017

Emmanuel S. Antonarakis

6

Emmanuel S Antonarakis

1 reference

6 July 2017

14

Michael Carducci

1 reference

6 July 2017

Ryan Phillips

2

1 reference

6 July 2017

Ashley Ross

3

1 reference

6 July 2017

Steven P Rowe

4

1 reference

6 July 2017

Stephen Greco

8

1 reference

6 July 2017

Samuel Denmeade

9

1 reference

6 July 2017

Channing Paller

10

1 reference

6 July 2017

Daniel Y Song

11

1 reference

6 July 2017

Maximilian Diehn

12

1 reference

6 July 2017

Hao Wang

13

1 reference

6 July 2017

Theodore L DeWeese

17

1 reference

6 July 2017

Adam Dicker

18

1 reference

6 July 2017

Mario Eisenberger

19

1 reference

6 July 2017

language of work or name

English

0 references

publication date

29 June 2017

1 reference

6 July 2017

1 reference

6 July 2017

volume

17

1 reference

6 July 2017

issue

1

1 reference

6 July 2017

page(s)

453

1 reference

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

6 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Stereotactic body radiation therapy: the report of AAPM Task Group 101.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Stereotactic body radiation therapy for inoperable early stage lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Stereotactic body radiation therapy for oligometastases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Stereotactic radiosurgery for the treatment of primary sarcomas and sarcoma metastases of the spine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy in pediatric brain tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Preoperative portal vein embolization and surgical resection in patients with hepatocellular carcinoma and small future liver remnant volume: comparison with transarterial chemoembolization

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Natural history of progression after PSA elevation following radical prostatectomy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5492934

Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186/S12885-017-3455-6

Image-guided robotic radiosurgery for spinal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/S12885-017-3455-6

Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/S12885-017-3455-6

Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/S12885-017-3455-6

Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/S12885-017-3455-6

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/S12885-017-3455-6

Is there a favorable subset of patients with prostate cancer who develop oligometastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/S12885-017-3455-6

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/S12885-017-3455-6

Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma

21 January 2018

1 reference

12 December 2020

Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients

1 reference

12 December 2020

Stereotactic single-dose radiotherapy of lung metastases

1 reference

12 December 2020

Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors

1 reference

12 December 2020

Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma

1 reference

12 December 2020

Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study

1 reference

12 December 2020

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

1 reference

12 December 2020

Stereotactic Body Radiation Therapy (SBRT) for lung metastases

1 reference

12 December 2020

Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy

1 reference

12 December 2020

A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases

1 reference

12 December 2020

10.1186/S12885-017-3455-6

Identifiers

DOI

1 reference

Dimensions Publication ID

6 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/s12885-017-3455-6

9 September 2019

1 reference

6 July 2017

1 reference